Clinical trials
Phase 1/2 Fallopian Tube Neoplasms trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
58 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2002 | 1 |
| 2004 | 3 |
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 1 |
| 2009 | 3 |
| 2010 | 3 |
| 2011 | 2 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 2 |
| 2016 | 8 |
| 2017 | 5 |
| 2018 | 4 |
| 2019 | 2 |
| 2020 | 2 |
| 2021 | 4 |
| 2022 | 6 |
| 2023 | 5 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 19 |
| Terminated | 14 |
| Recruiting | 11 |
| Active, not recruiting | 9 |
| Withdrawn | 2 |
| Unknown status | 2 |
| Suspended | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Cancer Institute (NCI) | 5 |
| M.D. Anderson Cancer Center | 4 |
| Roswell Park Cancer Institute | 3 |
| Imunon | 2 |
| Mayo Clinic | 2 |
| Pfizer | 2 |
| Regeneron Pharmaceuticals | 2 |
| 23andMe, Inc. | 1 |
| Abramson Cancer Center at Penn Medicine | 1 |
| Artios Pharma Ltd | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Fallopian Tube Neoplasms | 58 |
| Ovarian Neoplasms | 44 |
| Carcinoma, Ovarian Epithelial | 22 |
| Endometrial Neoplasms | 10 |
| Triple Negative Breast Neoplasms | 10 |
| Breast Neoplasms | 8 |
| Recurrence | 6 |
| Neoplasm Metastasis | 5 |
| Neoplasms | 5 |
| Carcinoma | 3 |
Trials
Showing 1 to 25 of 58. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.